|
CELG's Operating Income Growth by Quarter and Year
Celgene's Operating Income results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
Operating Income Growth Y/Y▼
|
Operating Income Growth Y/Y▼
|
CELG Operating Income (in millions $) |
FY 2019 |
FY 2018 |
FY 2017 |
FY 2016 |
IV Quarter |
December |
-
|
1,807.00
|
1,203.00
|
929.90
|
III Quarter |
September |
2,264.00
|
1,680.00
|
1,085.00
|
411.50
|
II Quarter |
June |
2,111.00
|
1,486.00
|
1,308.00
|
823.70
|
I Quarter |
March |
1,710.00
|
218.00
|
1,111.00
|
1,001.50
|
FY |
|
6,085.00
|
5,191.00
|
4,707.00
|
3,166.60
|
CELG Operating Income third quarter 2019 Y/Y Growth Comment |
Celgene Corp reported Operating Income improvement of 34.76% year on year in the third quarter 2019, to $ 2,264.00 millions, this is lower than Celgene Corp's recent average Operating Income rise of 73.99%.
Looking into third quarter 2019 results within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Operating Income growth. While Celgene Corp' s Operating Income rise of 34.76% ranks overall at the positon no. 536 in the third quarter 2019.
Explain Operating Income growth
|
CELG Operating Income ( Y/Y Growth %) |
2019
|
2018 |
2017 |
2016 |
IV Quarter |
December |
- |
50.21 % |
29.37 % |
3.3 % |
III Quarter |
September |
34.76 % |
54.84 % |
163.67 % |
416.96 % |
II Quarter |
June |
42.06 % |
13.61 % |
58.8 % |
98.1 % |
I Quarter |
March |
684.4 % |
-80.38 % |
10.93 % |
16.59 % |
FY |
|
- |
10.28 % |
48.65 % |
40.45 % |
CELG Operating Income (Quarter on Quarter Growth %) |
2019
|
2018 |
2017 |
2016 |
IV Quarter |
December |
- |
7.56 % |
10.88 % |
125.98 % |
III Quarter |
September |
7.25 % |
13.06 % |
-17.05 % |
-50.04 % |
II Quarter |
June |
23.45 % |
581.65 % |
17.73 % |
-17.75 % |
I Quarter |
March |
-5.37 % |
-81.88 % |
19.48 % |
11.25 % |
FY (Year on Year) |
|
- |
10.28 % |
48.65 % |
40.45 % |
Operating Income Y/Y Growth Statistics |
High |
Average |
Low |
684.4 % |
73.99 % |
-87.69 % |
(Mar 31 2019) |
|
(Sep 30 2015) |
|
Operating Income Y/Y Growth Statistics |
High |
Average |
Low |
684.4 % |
73.99 % |
-87.69 % |
(Mar 31 2019) |
|
(Sep 30 2015) |
|
Operating Income by Quarter for the Fiscal Years 2016, 2017, 2018, 2019 |
Celgene's Q/Q Operating Income Growth
Operating Income Q/Q Growth Statistics |
High |
Average |
Low |
1030.9 % |
42.04 % |
-81.88 % |
(Dec 31 2015) |
|
|
CELG's III. Quarter Q/Q Operating Income Comment |
Celgene Corp achieved in the III. Quarter 2019 below company average Operating Income increase of 7.25% quarter on quarter, to $ 2,264.00 millions.
Within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Operating Income quarter on quarter growth. While Celgene's Operating Income growth quarter on quarter, overall rank is 1041. |
|
|
Operating Income Q/Q Growth Statistics |
High |
Average |
Low |
1030.9 % |
42.04 % |
-81.88 % |
(Dec 31 2015) |
|
|
CELG's III. Quarter Q/Q Operating Income Comment |
Celgene Corp achieved in the III. Quarter 2019 below company average Operating Income increase of 7.25% quarter on quarter, to $ 2,264.00 millions.
Within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Operating Income quarter on quarter growth. While Celgene's Operating Income growth quarter on quarter, overall rank is 1041. |
|
Celgene's 12 Months Operating Income Growth Year on Year
Operating Income TTM Growth |
12 Months Ending (Sep 30 2019) |
12 Months Ending (Jun 30 2019) |
12 Months Ending (Mar 31 2019) |
12 Months Ending (Dec 31 2018) |
12 Months Ending (Sep 30 2018) |
Cumulative Operating Income 12 Months Ending |
$ 7,892.00 |
$ 7,308.00 |
$ 6,683.00 |
$ 5,191.00 |
$ 4,587.00 |
Y / Y Operating Income Growth (TTM) |
72.05 % |
83.07 % |
75.22 % |
10.28 % |
3.45 % |
Year on Year Operating Income Growth Overall
Ranking |
# 298 |
# 282 |
# 287 |
# 857 |
# 1268 |
Seqeuential Operating Income Change (TTM) |
7.99 % |
9.35 % |
28.74 % |
13.17 % |
14.9 % |
Seq. Operating Income Growth (TTM) Overall
Ranking |
# 829 |
# 674 |
# 196 |
# 451 |
# 676 |
Cumulative Operating Income growth
Comment |
Assuming the Celgene's fiscal year would have ended in Sep 30 2019, Celgene would have reprted above average annual Operating Income growth of 72.05% year on year, of $ 7,892 millions. This marks a slow-down of the companys growth trends and from the 83.07% increase in Jun 30 2019.
Within the Healthcare sector 30 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 282 to 298. |
Operating Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
267.29 % |
7.01 % |
-662.8 % |
|
|
|
|
|
Operating Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
267.29 % |
51.38 % |
-39.71 % |
|
|
|
Operating Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 21 |
Sector |
# 64 |
S&P 500 |
# 829 |
|
Cumulative Operating Income growth
Comment |
Assuming the Celgene's fiscal year would have ended in Sep 30 2019, Celgene would have reprted above average annual Operating Income growth of 72.05% year on year, of $ 7,892 millions. This marks a slow-down of the companys growth trends and from the 83.07% increase in Jun 30 2019.
Within the Healthcare sector 30 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 282 to 298. |
Operating Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
267.29 % |
7.01 % |
-662.8 % |
|
|
|
Operating Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
267.29 % |
51.38 % |
-39.71 % |
|
|
|
Operating Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 21 |
Sector |
# 64 |
S&P 500 |
# 829 |
|